Metsera Shares Soar to New High on $7.3-Billion Pfizer Merger Deal

Metsera Inc. (NASDAQ:MTSR) shares surged to an all-time high, jumping 60.80% to $53.58 after a $7.3 billion merger with Pfizer Inc. (NYSE: PFE). The acquisition price is $47.50 per share, with potential additional payments of up to $22.50 per share for three specific clinical milestones. The transaction is expected to close in Q4 2025.

In a significant move to bolster its obesity drug portfolio, Pfizer Inc. (NYSE: PFE) has announced its acquisition of Metsera Inc. (NASDAQ: MTSR) for $7.3 billion. The acquisition, which is expected to close in the fourth quarter of 2025, positions Pfizer to compete more effectively in the rapidly growing obesity therapeutics market.

The deal, valued at $47.50 per share, represents a 43% premium over Metsera's closing price on September 19, 2025. In addition to the initial cash outlay, Pfizer has included contingent value rights (CVRs) tied to specific clinical and regulatory milestones, which could increase the total deal value to $7.3 billion. These milestones include the initiation of Phase 3 trials, FDA approval, and commercial sales surpassing $1 billion annually Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market^[1].

The acquisition aligns with Pfizer's strategy to diversify its product portfolio and offset the looming patent cliffs from its COVID-19 vaccine. Obesity drugs represent a $100 billion-a-year market by 2030, and Metsera's emphasis on monthly-dosing GLP-1 receptor agonists aligns with patient demand for fewer administrations Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market^[1].

Metsera's pipeline includes several innovative therapies targeting GLP-1, amylin, and GIP pathways, which are key regulators of appetite and metabolism. Notably, MET-097i, a Phase 2 GLP-1 agonist, has shown promising results in early 2025, with 15–20% body weight reduction in 12 weeks and strong tolerability Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market^[1]. Additionally, Metsera's oral GLP-1 (MET-233i) is set for advancement in the fourth quarter of 2025, which could potentially disrupt the dominance of injectable therapies Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market^[1].

The market reacted positively to the news, with Metsera shares surging 59% pre-market on September 23, 2025, to close 36.6% higher. Pfizer shares rose 1.2% to $29.45, reflecting investor confidence in the deal Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market^[1]. Competitors showed mixed reactions, with Novo Nordisk dipping and Viking Therapeutics jumping on buyout speculation Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market^[1].

Analysts have expressed cautious optimism about the deal. Leerink Partners praised the potential for a $5 billion annual market share, while Goldman Sachs warned of integration risks. BTIG cited strong optionality for smaller biotech peers, and JPMorgan predicted Metsera's monthly dose could secure 20% market share by 2032 Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market^[1].

Pfizer plans to integrate Metsera's team into its New York HQ and expects MET-097i's Phase 2 extension topline results in the first quarter of 2026. However, the deal is not without risks, including clinical trial failures, antitrust hurdles, and patent disputes Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market^[1].

In conclusion, Pfizer's acquisition of Metsera represents a strategic move to re-enter the obesity drug race with innovative long-acting therapies. For investors, it's a wager on science, markets, and the expanding waistline of the world. The transaction is expected to close in the fourth quarter of 2025, pending regulatory and shareholder approvals.